Baum Hedlund is one of the nation’s leading law firms representing Paxil suicide and suicide attempt victims across the country. The firm has represented more than 100 victims or their family members   who either committed suicide or attempted suicide while taking Paxil or another antidepressant.  Many of those cases involve children and adolescents.

Since 1990, Baum Hedlund has been handling antidepressant-SSRI (selective serotonin reuptake inhibitors) suicide/violence cases and served on the Plaintiffs' Steering Committee in the first SSRI-suicide litigation involving Prozac (the first SSRI approved by the FDA for marketing in the U.S.).  They also served on the Plaintiffs Steering Committee MDL-1574) Paxil Products Liability Litigation.

Baum, Hedlund, Aristei & Goldman has extensive experience in litigating personal injury, wrongful death and consumer class action cases against major drug companies.  Our firm’s drug product liability litigation department has handled thousands of antidepressant product liability cases involving antidepressants including Prozac, Paxil and Zoloft against defendants such as Eli Lilly, GlaxoSmithKline and Pfizer.

Baum Hedlund maintains the highest *AV® peer review legal rating and is recognized as a preeminent plaintiff firm.   This firm also has the longest track-record handling SSRI antidepressant litigation.

While representing our clients, we dig deep into drug company files to discover the truth about what the company knew about the drug’s risks, when the company knew of those risks and what efforts, if any, the company took to hide those risks. Only through legal action can anyone gain access to this type of information.

Our attorneys are strong public health advocates.  They have fought and continue to fight for proper warnings on pharmaceutical drugs.  As an example, our firm testified about the dangers of SSRI antidepressants on several occasions before the Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee.  Baum Hedlund attorneys, staff and clients have also met with FDA and Department of Health and Human Resources officials, as well as met with members of the U.S. House and Senate regarding the risk of antidepressant induced suicidality.  We also assisted Congressional Investigators from two separate committees investigating pharmaceutical executives and FDA officials concerning antidepressants and their association with suicidality.

Past efforts by Baum Hedlund and others have resulted in improvements in drug safety including the FDA black box suicide warning issued on certain antidepressants.